Selina M. Luger

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member , Abramson Cancer Center, University of Pennsylvania
Director, Outpatient Practice, Stem Cell Transplant & Hematological Malignancies, Hospital of the University of Pennsylvania
Director, Leukemia Program, Abramson Cancer Center, Perelman School of Medicine
Member, Electronic Medical Record Oversight Committee
Member, Sunrise Physician Advisory Board
Chair, Hematology-Oncology Epic Governance, Perelman School of Medicine, University of Pennsylvania
Member, Clinical Leadership Committee, Department of Medicine
Member, Epic Operations Committee, Hospital of the University of Pennsylvania
Medical Board, Member, Executive Committee, Hospital of the University of Pennsylvania
Member, Penn Chart Development Committee, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Hematology-Oncology
Perelman Center 2 West
34th and Civic Center Blvd
Philadelphia, PA 19104
Office: 2156141847
Fax: 2156624064
Education:
A.B. (Biochemistry)
Harvard University, 1982.
M.D.CM (Medicine)
McGill University, 1987.
Permanent link
 

Description of Research Expertise

Leukemia, myelodysplastic syndrome, myeloproliferative disorders
MDS, AML, CML, ALL

Description of Itmat Expertise

Dr. Luger conducts translational research in leukemia, MDS and other hematologic malignancies.

Selected Publications

DiPersio JF1, Erba HP2, Larson RA3, Luger SM4, Tallman MS5, Brill JM6, Vuagniaux G7, Rouits E7, Sorensen JM6, Zanna C7. : Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study. Clin Lymphoma Myeloma Leuk Mar 2015.

Orlowski RJ1, Mangan JK, Luger SM. : Approach to patients with primary refractory acute myeloid leukemia. Curr Opin Hematol Mar 2015.

Singh N1, Qayyum S, Wasik MA, Luger SM. : Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy. Am J Hematol Feb 2015.

Sehgal AR1, Gimotty PA2, Zhao J3, Hsu JM4, Daber R3, Morrissette JD5, Luger SM6, Loren AW4, Carroll M7. : DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res Jan 2015.

Perez-Andreu V1, Roberts KG2, Xu H3, Smith C1, Zhang H1, Yang W1, Harvey RC4, Payne-Turner D2, Devidas M5, Cheng IM6, Carroll WL7, Heerema NA8, Carroll AJ9, Raetz EA10, Gastier-Foster JM11, Marcucci G12, Bloomfield CD12, Mrózek K12, Kohlschmidt J13, Stock W14, Kornblau SM15, Konopleva M16, Paietta E17, Rowe JM18, Luger SM19, Tallman MS20, Dean M21, Burchard EG22, Torgerson DG22, Yue F23, Wang Y23, Pui CH24, Jeha S24, Relling MV1, Evans WE1, Gerhard DS25, Loh ML26, Willman CL6, Hunger SP27, Mullighan CG2, Yang JJ1. : A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. Jan 2015.

Bagley SJ1, Sehgal AR2, Gill S3, Frey NV3, Hexner EO3, Loren AW3, Mangan JK3, Porter DL3, Stadtmauer EA3, Reshef R3, Luger SM3. : Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition. Biol Blood Marrow Transplant Dec 2014.

Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE. : Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol Sep 2014.

Reshef Ran, Hexner Elizabeth O, Loren Alison W, Frey Noelle V, Stadtmauer Edward A, Luger Selina M, Mangan James K, Gill Saar I, Vassilev Pavel, Lafferty Kathryn A, Smith Jacqueline, Van Deerlin Vivianna M, Mick Rosemarie, Porter David L: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Jul 2014.

Fielding Adele K, Rowe Jacob M, Buck Georgina, Foroni Letizia, Gerrard Gareth, Litzow Mark R, Lazarus Hillard, Luger Selina M, Marks David I, McMillan Andrew K, Moorman Anthony V, Patel Bella, Paietta Elisabeth, Tallman Martin S, Goldstone Anthony H: UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6): 843-50, Feb 2014.

Hexner Elizabeth, Roboz Gail, Hoffman Ron, Luger Selina, Mascarenhas John, Carroll Martin, Clementi Regina, Bensen-Kennedy Debra, Moliterno Alison: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology 164(1): 83-93, Jan 2014.

back to top
Last updated: 07/07/2015
The Trustees of the University of Pennsylvania